National trends indicate that the utilization of cytoreductive surgery (CRS) for metastatic colorectal cancer (mCRC) increased from 33.1% in 2004 to 38.3% in 2015. In a cohort of 88,593 patients, those undergoing CRS exhibited significantly better overall survival (OS) compared to non-surgical patients, with median OS at 34.4 months, versus 13.2 months for no surgery. Additionally, patients receiving hyperthermic intraperitoneal chemotherapy (HIPEC) showed further OS improvement (30.2 months) compared to non-HIPEC patients.
Journal Article by Young S, Greene J (…) Bilchik A et 3 al. in J Surg Oncol
© 2025 Wiley Periodicals LLC.